Clinical trials: Tace
Hepatocellular Carcinoma
Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC
This study will evaluate the role of everolimus in combination with local Transcatheter Arterial Chemoembolization (TACE) procedure in patients with localized unresectable Hepatocellular Carcinoma (HCC).
- Trial name
- TRACER (NCT01379521)
- Testing
- everolimus
- Where
- 5 sites in Hong Kong, Taiwan and 1 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Hepatocellular Carcinoma
A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of TAC-101 after Transcatheter Arterial Chemoembolization (TACE) in patients with advanced, unresectable hepatocellular carcinoma (HCC) who are being scheduled for…
- Trial name
- NCT00756782
- Testing
- TAC-101
- Sponsor
- Taiho Oncology, Inc.
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS) and Overall Survival(OS), achieved by HX008 Plus Transcatheter Arterial Chemoembolization (TACE) or Temozolomide…
- Trial name
- NCT05647954
- Testing
- HX008 + TACE, Temozolomide + TACE, Pembrolizumab
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
This is a multicenter, randomized, open-label, controlled Phase 2 study in patients with unresectable hepatocellular carcinoma (uHCC).
- Trial name
- NCT07209813
- Testing
- GKL-006 Injection, TACE
- Where
- 7 sites in China
- Volunteers
- 48 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Unresectable, Non-metastatic Hepatocellular Carcinoma
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
To evaluate the efficacy and safety of AK104 plus lenvatinib combined with on-demand TACE in participants with unresectable, non-metastatic hepatocellular carcinoma
- Trial name
- NCT05319431
- Testing
- AK104, Lenvatinib, TACE
- Where
- 5 sites in China
- Volunteers
- 60 people
- Sponsor
- Akeso
Hepatocellular Carcinoma
SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma
This study is open to patients with primary HCC who cannot be treated by potentially curative treatment modalities, such as surgical resection, liver transplantation or percutaneous ablation.
- Trial name
- SIRTACE (NCT00867750)
- Testing
- Radioembolisation (SIR-Spheres® microspheres), Transarterial Chemoembolisation
- Where
- 2 sites in Germany, Spain
- Volunteers
- 28 people
- Sponsor
- Sirtex Medical
Hepato Cellular Carcinoma (HCC)
Evaluate the Effect of Tirazamine on Primary Liver Cancer.
This Phase I/II trial aims to evaluate the pharmacokinetics, efficacy, and safety of tirapazamine administered via hepatic artery injection followed by TACE in patients with intermediate-stage HCC.
- Trial name
- NCT06848556
- Testing
- tirapazamine, Transarterial Embolization, TACE
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Carcinoma, Hepatocellular
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic…
- Trial name
- NCT04246177
- Testing
- Lenvatinib, Pembrolizumab, TACE
- Where
- 205 sites in United States, Australia and 25 more
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Hepatocellular
Safety and Efficacy of "Immuncell-LC" in TACE Therapy
To evaluate the efficacy and safety of 'Immuncell-LC group' and 'non-treatment group' in the patients undergone Transarterial Chemoembolization for intermediate stage hepatocellular carcinoma
- Trial name
- NCT02856815
- Testing
- Immuncell-LC
- Where
- 3 sites in South Korea
- Volunteers
- 76 people
- Sponsor
- GC Cell Corporation
Hepatocellular Carcinoma Non-resectable
BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)
The primary objective of the study is to confirm safety and technical success of BioPearl™ microspheres loaded with Doxorubicin in the treatment of unresectable hepatocellular carcinoma (HCC).
- Trial name
- BIOPEARL-ONE (NCT05911633)
- Testing
- BioPearl™
- Where
- 10 sites in Belgium, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Terumo Europe N.V.
Carcinoma, Hepatocellular
Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China
This study is to obtain the characteristics and treatment pattern of the unresectable HCC patients who are candidates for systemic therapy and in whom a decision to treat with sorafenib from early stage of TACE treatment course…
- Trial name
- SUCCESS (NCT01839630)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre Post-market Follow-up Study.
The primary objective of the study is to confirm safety and efficacy of BioPearl™ microspheres loaded with doxorubicin in the treatment of patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- BIOPEARL-FIRST (NCT04231929)
- Testing
- Chemoembolization
- Where
- 3 sites in Belgium
- Sponsor
- Terumo Europe N.V.
Hepatocellular Carcinoma
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
The purpose of this study is to evaluate overall survival in patients diagnosed with hepatocellular cancer (HCC) treated with HepaSphere/QuadraSphere Microspheres loaded with chemotherapeutic agent doxorubicin compared to…
- Trial name
- HiQuality (NCT01387932)
- Testing
- HepaSphere/QuadraSphere Microspheres, PVA, lipiodol, doxorubicin
- Where
- 23 sites in United States, Belgium and 3 more
- Volunteers
- 235 people
- Sponsor
- Merit Medical Systems, Inc.
Hepatocellular Carcinoma
A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA
A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of Autologous Cytokine-Induced Killer (CIK) Cell for Patients with Hepatocellular Carcinoma (HCC) after Transarterial Chemoembolization (TACE), Percutaneous…
- Trial name
- NCT03124498
- Testing
- CIK Cell
- Volunteers
- 55 people
- Sponsor
- Chuan An Biotechnology Co., Ltd.
Primary Hepatocellular Carcinoma
Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
Although liver resection, liver transplantation, a-interferon, Transarterial Chemo Embolization (TACE), percutaneous ethanol injection (PEI), Percutaneous microwave coagulation therapy (PMCT), Radiofrequency ablation (RFA)…
- Trial name
- DC-TC (NCT01828762)
- Testing
- DC-TC+GM-CSF
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Shanghai AbelZeta Ltd.
Hepatocellular Carcinoma
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
- Trial name
- NCT07691762
- Testing
- SHR-8068 + Adebrelimab + Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 690 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.